IFG Advisory LLC Has $1.19 Million Position in Pfizer Inc. (NYSE:PFE)

IFG Advisory LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 51.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,188 shares of the biopharmaceutical company's stock after selling 43,338 shares during the period. IFG Advisory LLC's holdings in Pfizer were worth $1,186,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of PFE. RB Capital Management LLC increased its stake in Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company's stock worth $282,000 after buying an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. boosted its holdings in shares of Pfizer by 1.1% during the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company's stock worth $1,868,000 after purchasing an additional 400 shares during the last quarter. United Bank boosted its holdings in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company's stock worth $2,416,000 after purchasing an additional 290 shares during the last quarter. Ergoteles LLC boosted its holdings in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company's stock worth $1,903,000 after purchasing an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company's stock worth $69,238,000 after purchasing an additional 79,887 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on PFE shares. TD Cowen cut Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective on the stock. UBS Group decreased their price objective on Pfizer from $34.00 to $27.00 and set a "neutral" rating on the stock in a report on Thursday, December 14th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a report on Friday, March 1st. Finally, Argus cut Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $36.88.

Pfizer Stock Performance

NYSE:PFE traded down $0.03 during mid-day trading on Thursday, reaching $27.75. The stock had a trading volume of 39,620,254 shares, compared to its average volume of 43,835,094. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $42.22. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market capitalization of $157.14 billion, a price-to-earnings ratio of 77.08, a PEG ratio of 1.24 and a beta of 0.61. The business has a 50 day simple moving average of $27.46 and a 200 day simple moving average of $29.46.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analysts' expectations of $14.37 billion. During the same period last year, the company posted $1.14 earnings per share. The firm's quarterly revenue was down 41.3% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.